A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 6000
- Registration Number
- NCT05683561
A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 518
- Registration Number
- NCT05652543
- Locations
- 🇨🇳
Dazhu County Center for Disease Control and Prevention, Dazhou, Si Chuan, China
🇨🇳Lianshui County Center for Disease Control and Prevention, Lianshui, Jiangsu, China
🇨🇳Jiangsu Center for Disease Control and Prevention, Nanjing, Jiangsu, China
SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05552807
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, China
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT05522829
This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 446
- Registration Number
- NCT05480293
- Locations
- 🇨🇳
Beijing Tongren Hospital, Beijing, China
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT05345873
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT05329051
A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 1800
- Registration Number
- NCT05323461
- Locations
- 🇦🇪
Al Kuwait Hospital (Al Baraha Hospital), Dubai, United Arab Emirates
A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 10000
- Registration Number
- NCT05308576
- Locations
- 🇨🇳
Guizhou center for disease control and prevention, Guiyang, Guizhou, China
A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Sinocelltech Ltd.
- Registration Number
- NCT05308602
© Copyright 2024. All Rights Reserved by MedPath